PRadR: PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer, a multicentric phase I/II. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results